Q101-pegylated recombinant human interferon alpha-2a (Shijiazhuang Zhongqi Pharmaceutical)

Q101-聚乙二醇重组人干扰素α2a（石药集团中奇制药）

Report date: 2022/07/15 15:12:33

Base Information

Drug NameQ101-pegylated recombinant human interferon alpha-2a (Shijiazhuang Zhongqi Pharmaceutical)
Drug Alias NamePEG-IFN-α-2aQ-101 (Shijiazhuang Zhongqi Pharmaceutical)
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsHepatitis B
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesCSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd
Inactive CompaniesN/A
Active IndicationsHepatitis B
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A